CharlesKing
2021-12-17
Like and comment plz👇👇👇
Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain<blockquote>Adagio Therapeutics继续其狂野之旅——两项测试如何带来三位数的收益</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":690481576,"tweetId":"690481576","gmtCreate":1639701531165,"gmtModify":1639701531765,"author":{"id":3579391265651951,"idStr":"3579391265651951","authorId":3579391265651951,"authorIdStr":"3579391265651951","name":"CharlesKing","avatar":"https://static.tigerbbs.com/d8fbdcf3295ba7f84c1f2205610ea968","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":59,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like and comment plz👇👇👇</p></body></html>","htmlText":"<html><head></head><body><p>Like and comment plz👇👇👇</p></body></html>","text":"Like and comment plz👇👇👇","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690481576","repostId":2192194909,"repostType":4,"repost":{"id":"2192194909","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1639701314,"share":"https://www.laohu8.com/m/news/2192194909?lang=zh_CN&edition=full","pubTime":"2021-12-17 08:35","market":"us","language":"en","title":"Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain<blockquote>Adagio Therapeutics继续其狂野之旅——两项测试如何带来三位数的收益</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2192194909","media":"Investors","summary":"New analyses suggest Adagio Therapeutics' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.","content":"<p>New analyses suggest <b><a href=\"https://laohu8.com/S/ADGI\">Adagio Therapeutics</a></b>' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.</p><p><blockquote>新的分析表明<b><a href=\"https://laohu8.com/S/ADGI\">柔板疗法</a></b>“新冠抗体仍然可以应对奥密克戎病毒变种——ADGI股价周四飙升。</blockquote></p><p> Two studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee在给客户的一份报告中写道，美国和法国知名实验室的两项研究表明，Adagio的实验性抗体药物ADG20可以对抗奥密克戎病毒引发的新冠病毒。作为回应，ADGI股价飙升106%，接近13.10。</blockquote></p><p> The news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with <b>Vir Biotechnology</b> and <b>GlaxoSmithKline</b>. Also this week, the duo said their antibody could effectively target omicron.</p><p><blockquote>这一消息与本周早些时候发生了180度的转变，当时Adagio表示其抗体对抗奥密克戎病的有效性大幅下降后，股价暴跌。Yee说，现在Adagio药物似乎正在与<b>维尔生物技术</b>和<b>葛兰素史克</b>同样在本周，两人表示，他们的抗体可以有效地靶向奥密克戎。</blockquote></p><p> \"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.</p><p><blockquote>“因此，也许Adagio（药物ADG20）并不像之前想象的那么糟糕，并且处于葛兰素史克/Vir的大致范围内，这意味着它具有实用性和（有效性）并且具有真正的作用，”Yee说。</blockquote></p><p> <h2>ADGI Stock Continues Its Wild Ride</h2> Antibody drugs have taken a wild ride on the omicron train.</p><p><blockquote><h2>ADGI股票继续疯狂上涨</h2>抗体药物在奥密克戎列车上狂奔。</blockquote></p><p> Vaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.</p><p><blockquote>疫苗促使身体产生阻断病毒的抗体。另一方面，基于抗体的治疗只是简单地给一个人输注或注射病毒阻断剂。</blockquote></p><p> But omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.</p><p><blockquote>但奥密克戎病毒的刺突蛋白包含许多突变，因此抗体发现它更难识别。Adagio此前表示，奥密克戎的任何突变都不会损害其药物的有效性。但是，周二，ADGI股价暴跌，此前该公司表示该理论在进一步测试中并未成功。</blockquote></p><p> \"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.</p><p><blockquote>“我们说这是一个巨大的惊喜，因为所有数据都表明他们的药物应该对奥密克戎病有效，甚至Adagio管理层也一直表示，他们之前的所有工作都表明保守结合区和其他因素应该使其成为一种很好的抗体。奥密克戎和未来的变种，”Yee说。</blockquote></p><p> The news on Thursday resulted in another flip for ADGI stock, however.</p><p><blockquote>然而，周四的消息导致ADGI股价再次上涨。</blockquote></p><p> The laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.</p><p><blockquote>实验室发现，奥密克戎导致ADG20对抗奥密克戎的有效性降低20-40倍。Yee说，这比Adagio周二估计的300倍下降要好。他对ADGI股票的目标价为46美元。</blockquote></p><p> <h2>Other Antibodies Target Omicron</h2> Similarly, on Thursday, <b>AstraZeneca</b> said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.</p><p><blockquote><h2>其他抗体靶向奥密克戎</h2>同样，周四，<b>阿斯利康</b>称其抗体对抗奥密克戎病毒的效果不如对抗原始毒株。但阿斯利康表示，这种名为Evusheld的药物仍然可以针对奥密克戎病。</blockquote></p><p> AstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.</p><p><blockquote>今天股市午盘交易中，阿斯利康股价上涨1.87%，接近56.70点。Vir股价继续连续六天上涨，上涨8.5%，接近56点。根据MarketSmith.com的数据，周三，Vir股票突破了带手柄的杯子底部，买入点为52.95。</blockquote></p><p> Meanwhile, <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.</p><p><blockquote>同时，<b><a href=\"https://laohu8.com/S/REGN\">再生元制药</a></b>股价在635点附近下跌3.5%。该公司表示，其目前授权的抗体方案对奥密克戎病毒失去了效力。但是，再生元表示，其下一代抗体可以针对奥密克戎和德尔塔。然而，这些抗体没有授权。</blockquote></p><p> It's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.</p><p><blockquote>值得注意的是，ADGI股票在IBD Digital指标中的评级较低。该股的相对强度评级为1，处于最低水平，其12个月表现在所有股票中排名垫底1%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain<blockquote>Adagio Therapeutics继续其狂野之旅——两项测试如何带来三位数的收益</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain<blockquote>Adagio Therapeutics继续其狂野之旅——两项测试如何带来三位数的收益</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time smaller\">2021-12-17 08:35</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>New analyses suggest <b><a href=\"https://laohu8.com/S/ADGI\">Adagio Therapeutics</a></b>' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.</p><p><blockquote>新的分析表明<b><a href=\"https://laohu8.com/S/ADGI\">柔板疗法</a></b>“新冠抗体仍然可以应对奥密克戎病毒变种——ADGI股价周四飙升。</blockquote></p><p> Two studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee在给客户的一份报告中写道，美国和法国知名实验室的两项研究表明，Adagio的实验性抗体药物ADG20可以对抗奥密克戎病毒引发的新冠病毒。作为回应，ADGI股价飙升106%，接近13.10。</blockquote></p><p> The news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with <b>Vir Biotechnology</b> and <b>GlaxoSmithKline</b>. Also this week, the duo said their antibody could effectively target omicron.</p><p><blockquote>这一消息与本周早些时候发生了180度的转变，当时Adagio表示其抗体对抗奥密克戎病的有效性大幅下降后，股价暴跌。Yee说，现在Adagio药物似乎正在与<b>维尔生物技术</b>和<b>葛兰素史克</b>同样在本周，两人表示，他们的抗体可以有效地靶向奥密克戎。</blockquote></p><p> \"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.</p><p><blockquote>“因此，也许Adagio（药物ADG20）并不像之前想象的那么糟糕，并且处于葛兰素史克/Vir的大致范围内，这意味着它具有实用性和（有效性）并且具有真正的作用，”Yee说。</blockquote></p><p> <h2>ADGI Stock Continues Its Wild Ride</h2> Antibody drugs have taken a wild ride on the omicron train.</p><p><blockquote><h2>ADGI股票继续疯狂上涨</h2>抗体药物在奥密克戎列车上狂奔。</blockquote></p><p> Vaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.</p><p><blockquote>疫苗促使身体产生阻断病毒的抗体。另一方面，基于抗体的治疗只是简单地给一个人输注或注射病毒阻断剂。</blockquote></p><p> But omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.</p><p><blockquote>但奥密克戎病毒的刺突蛋白包含许多突变，因此抗体发现它更难识别。Adagio此前表示，奥密克戎的任何突变都不会损害其药物的有效性。但是，周二，ADGI股价暴跌，此前该公司表示该理论在进一步测试中并未成功。</blockquote></p><p> \"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.</p><p><blockquote>“我们说这是一个巨大的惊喜，因为所有数据都表明他们的药物应该对奥密克戎病有效，甚至Adagio管理层也一直表示，他们之前的所有工作都表明保守结合区和其他因素应该使其成为一种很好的抗体。奥密克戎和未来的变种，”Yee说。</blockquote></p><p> The news on Thursday resulted in another flip for ADGI stock, however.</p><p><blockquote>然而，周四的消息导致ADGI股价再次上涨。</blockquote></p><p> The laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.</p><p><blockquote>实验室发现，奥密克戎导致ADG20对抗奥密克戎的有效性降低20-40倍。Yee说，这比Adagio周二估计的300倍下降要好。他对ADGI股票的目标价为46美元。</blockquote></p><p> <h2>Other Antibodies Target Omicron</h2> Similarly, on Thursday, <b>AstraZeneca</b> said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.</p><p><blockquote><h2>其他抗体靶向奥密克戎</h2>同样，周四，<b>阿斯利康</b>称其抗体对抗奥密克戎病毒的效果不如对抗原始毒株。但阿斯利康表示，这种名为Evusheld的药物仍然可以针对奥密克戎病。</blockquote></p><p> AstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.</p><p><blockquote>今天股市午盘交易中，阿斯利康股价上涨1.87%，接近56.70点。Vir股价继续连续六天上涨，上涨8.5%，接近56点。根据MarketSmith.com的数据，周三，Vir股票突破了带手柄的杯子底部，买入点为52.95。</blockquote></p><p> Meanwhile, <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.</p><p><blockquote>同时，<b><a href=\"https://laohu8.com/S/REGN\">再生元制药</a></b>股价在635点附近下跌3.5%。该公司表示，其目前授权的抗体方案对奥密克戎病毒失去了效力。但是，再生元表示，其下一代抗体可以针对奥密克戎和德尔塔。然而，这些抗体没有授权。</blockquote></p><p> It's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.</p><p><blockquote>值得注意的是，ADGI股票在IBD Digital指标中的评级较低。该股的相对强度评级为1，处于最低水平，其12个月表现在所有股票中排名垫底1%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192194909","content_text":"New analyses suggest Adagio Therapeutics' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.\nTwo studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.\nThe news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with Vir Biotechnology and GlaxoSmithKline. Also this week, the duo said their antibody could effectively target omicron.\n\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.\nADGI Stock Continues Its Wild Ride\nAntibody drugs have taken a wild ride on the omicron train.\nVaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.\nBut omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.\n\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.\nThe news on Thursday resulted in another flip for ADGI stock, however.\nThe laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.\nOther Antibodies Target Omicron\nSimilarly, on Thursday, AstraZeneca said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.\nAstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.\nMeanwhile, Regeneron Pharmaceuticals stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.\nIt's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.","news_type":1,"symbols_score_info":{"ADGI":0.9}},"isVote":1,"tweetType":1,"viewCount":2903,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":23,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/690481576"}
精彩评论